The society of thoracic surgeons, the society of cardiovascular anesthesiologists, and the American society of extracorporeal technology: Clinical practice guidelines - Anticoagulation during cardiopulmonary bypass

Anesthesia and Analgesia

Volumn 126, Issue 2, 2018, Pages 413-424

  Shore Lesserson, Linda ^a   Baker, Robert A ^b   Ferraris, Victor A ^c   Greilich, Philip E ^d   Fitzgerald, David ^e   Roman, Philip ^f   Hammon, John W ^g  

^a Northshore University Hospital   (United States)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f ST ANTHONY HOSPITAL   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BIVALIRUDIN; HEPARIN;

ABSTRACT REPORT; ANTICOAGULANT THERAPY; ARTICLE; CARDIOPULMONARY BYPASS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG MONITORING; EVIDENCE BASED PRACTICE; HEART SURGERY; HUMAN; INTERDISCIPLINARY RESEARCH; MEDICAL INFORMATION; MEDICAL SOCIETY; MEDICAL SUBJECT HEADINGS; MEDLINE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PUBLICATION; QUALITY CONTROL; SYSTEMATIC REVIEW; ANESTHESIOLOGIST; EXTRACORPOREAL CIRCULATION; PROCEDURES; STANDARDS; THORAX SURGERY;

ANESTHESIOLOGISTS; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; EXTRACORPOREAL CIRCULATION; HEPARIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; THORACIC SURGICAL PROCEDURES;

EID: 85051844513     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000002613     Document Type: Article

References (118)

1. Stoney WS. Evolution of cardiopulmonary bypass. Circulation. 2009;119:2844-2853.
2. Ferraris VA. Heroes and evidence. J Thorac Cardiovasc Surg. 2002;124:11-13.
3. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69:674-684.
4. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978;26:231-240.
5. Na S. Stabilized infective endocarditis and altered heparin responsiveness during cardiopulmonary bypass. World J Surg 2009;33:1862-7.
6. Garvin S, FitzGerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg. 2010;111:849-855.
7. Grima C. The effects of intermittent prebypass heparin dosing in patients undergoing coronary artery bypass grafting. Perfusion. 2003;18:283-289.
8. Neema PK, Sinha PK, Rathod RC. Activated clotting time during cardiopulmonary bypass: is repetition necessary during open heart surgery? Asian Cardiovasc Thorac Ann. 2004;12:47-52.
9. Shore-Lesserson L. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth. 2005;9:41-52.
10. Machin D, Devine P. The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement. J Extra Corpor Technol. 2005;37:265-271.
11. Leyvi G, Shore-Lesserson L, Harrington D, Vela-Cantos F, Hossain S. An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation. Anesth Analg. 2001;92:578-583.
12. Koster A, Fischer T, Praus M et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology. 2002;97:837-841.
13. Despotis GJ, Joist JH, Hogue CW Jr et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46-54.
14. Despotis GJ, Joist JH, Hogue CW Jr et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost. 1996;76:902-908.
15. Pappalardo F, Franco A, Crescenzi G, De Simone F, Torracca L, Zangrillo A. Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion. 2006;21:285-290.
16. Hofmann B, Bushnaq H, Kraus FB et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion. 2013;28:412-418.
17. Newsome J, Stipanovich K, Flaherty S. Comparison of heparin administration using the Rapidpoint Coag and Hepcon HMS. J Extra Corpor Technol. 2004;36:139-144.
18. Hansen R, Koster A, Kukucka M, Mertzlufft F, Kuppe H. A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: a pilot investigation. Anesth Analg. 2000;91:533-538.
19. Hellstern P, Bach J, Simon M, Saggau W. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest- POC-Hi. J Extra Corpor Technol. 2007;39:81-86.
20. Gravlee GP, Haddon WS, Rothberger HK et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg. 1990;99:518-527.
21. Gravlee GP, Rogers AT, Dudas LM et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology. 1992;76:393-401.
22. Ichikawa J, Kodaka M, Nishiyama K, Hirasaki Y, Ozaki M, Komori M. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28:1003-1007.
23. Bosch YP, Ganushchak YM, de Jong DS. Comparison of ACT point-of-care measurements: repeatability and agreement. Perfusion. 2006;21:27-31.
24. Wallock M, Jeske WP, Bakhos M, Walenga JM. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Perfusion. 2001;16:147-153.
25. Leyvi G, Zhuravlev I, Inyang A et al. Arterial versus venous sampling for activated coagulation time measurements during cardiac surgery: a comparative study. J Cardiothorac Vasc Anesth. 2004;18:573-580.
26. Searles B, Nasrallah F, Darling E, Yarcusko S. How does the age of a blood sample affect it's activated clotting time? Comparison of eight different devices. J Extra Corpor Technol. 2002;34:175-177.
27. Welsby IJ, McDonnell E, El-Moalem H, Stafford-Smith M, Toffaletti JG. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. J Clin Monit Comput. 2002;17:287-292.
28. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 2: Calculating the overestimation of heparin by the activated clotting time. Perfusion. 2003;18:277-281.
29. Patteril M, Stafford-Smith M, Toffaletti JG, Bute BP, Milano CA, Welsby IJ. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery. Clin Chim Acta. 2005;356:218-224.
30. Chavez JJ, Foley DE, Snider CC et al. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass. Anesth Analg. 2004;99:1290-4; table of contents.
31. Ganter MT, Monn A, Tavakoli R et al. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Eur J Cardiothorac Surg. 2006;30:278-284.
32. Ganter MT, Monn A, Tavakoli R, Klaghofer R, Zollinger A, Hofer CK. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2007;21:524-528.
33. Watson H, Davidson S, Keeling D, Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012;159:528-40.
34. Prechel MM, Walenga JM. Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia. Thromb J. 2013;11:7.
35. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy. 2006;61:1432-1440.
36. Centers for Disease Control. Acute allergic-type reactions among patients undergoing hemodialysis-multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008;57:124-5.
37. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med 2015;373:252-61.
38. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost. 2016;116:813-822.
39. Kerendi F, Thourani VH, Puskas JD, et al. Impact of heparininduced thrombocytopenia on postoperative outcomes after cardiac surgery. Ann Thorac Surg 2007;84:1548-55.
40. Bennett-Guerrero E, Slaughter TF, White WD et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg. 2005;130:1567-1572.
41. Kress DC, Aronson S, McDonald ML et al. Positive heparinplatelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg. 2007;83:1737-1743.
42. Stribling WK, Slaughter TF, Houle TT, Sane DC. Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J. 2007;153:900-906.
43. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl):e495-530.
44. Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood. 2008;112:4024-4027.
45. Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood. 2014;123:2485-2493.
46. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidencebased clinical practice guidelines (8th edition). Chest 2008;133(Suppl):340-80.
47. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest. 2002;122:37-42.
48. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
49. Nuttall GA, Oliver WC Jr, Santrach PJ et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg. 2003;96:344-50, table of contents.
50. Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparininduced thrombocytopenia. N Engl J Med. 2000;343:515.
51. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin- release assay. Am J Hematol. 2015;90:564-572.
52. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2015;41:49-60.
53. Piednoir P, Allou N, Provenchère S et al. Heparin-induced thrombocytopenia after cardiac surgery: an observational study of 1,722 patients. J Cardiothorac Vasc Anesth. 2012;26:585-590.
54. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.
55. Lillo-Le Louet A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004;2:1882-8.
56. Cuker A, Arepally G, Crowther MA et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8:2642-2650.
57. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120:4160-4167.
58. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
59. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
60. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparindependent antibodies. Br J Haematol. 2005;128:837-841.
61. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(Suppl):311-37.
62. Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy. 2004;34:1916-1918.
63. Grims RH, Weger W, Reiter H, Arbab E, Kränke B, Aberer W. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol. 2007;157:514-517.
64. Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul Fibrinolysis. 2006;17:605-613.
65. Koster A, Spiess B, Chew DP et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2004;93:356-359.
66. Zucker ML, Koster A, Prats J, Laduca FM. Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corpor Technol. 2005;37:364-368.
67. Merry AF. Focus on thrombin: alternative anticoagulants. Semin Cardiothorac Vasc Anesth. 2007;11:256-260.
68. Nagle EL, Tsu LV, Dager WE. Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy. Ann Pharmacother. 2011;45:e47.
69. Koster A, Dyke CM, Aldea G et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007;83:572-577.
70. Dyke CM, Smedira NG, Koster A et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533-539.
71. Stratmann G, deSilva AM, Tseng EE et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004;98:1635-9, table of contents.
72. Koster A, Buz S, Krabatsch T et al. Effect of modified ultrafiltration on bivalirudin elimination and postoperative blood loss after on-pump coronary artery bypass grafting: assessment of different filtration strategies. J Card Surg. 2008;23:655-658.
73. Schwartz J, Winters JL, Padmanabhan A et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidencebased approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28:145-284.
74. Welsby IJ, Um J, Milano CA, Ortel TL, Arepally G. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg. 2010;110:30-35.
75. Warkentin TE, Sheppard JA, Chu FV, Kapoor A, Crowther MA, Gangji A. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood. 2015;125:195-198.
76. Addonizio VP Jr, Fisher CA, Kappa JR, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery. 1987;102:796-807.
77. Palatianos GM, Foroulis CN, Vassili MI et al. Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost. J Thorac Cardiovasc Surg. 2004;127:548-554.
78. Koster A, Kukucka M, Bach F et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology. 2001;94:245-251.
79. Tanigawa Y, Yamada T, Matsumoto K, Nakagawachi A, Torikai A, Sakaguchi Y. Non-recovery of ACT in a patient with heparininduced thrombocytopenia type II during mitral valve replacement using argatroban anticoagulation. J Anesth. 2013;27:951-955.
80. Genzen JR, Fareed J, Hoppensteadt D et al. Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. Transfusion. 2010;50:801-807.
81. Agarwal S, Ullom B, Al-Baghdadi Y, Okumura M. Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol. 2012;28:106-110.
82. Follis F, Filippone G, Montalbano G et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg. 2010;10:592-596.
83. Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2007;21:113-126.
84. Galeone A, Rotunno C, Guida P et al. Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery. J Cardiothorac Vasc Anesth. 2013;27:853-858.
85. Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth. 1997;11:24-28.
86. Guo Y, Tang J, Du L et al. Protamine dosage based on two titrations reduces blood loss after valve replacement surgery: a prospective, double-blinded, randomized study. Can J Cardiol. 2012;28:547-552.
87. Shigeta O, Kojima H, Hiramatsu Y et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;118:354-360.
88. Runge M, Møller CH, Steinbrüchel DA. Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study. J Extra Corpor Technol. 2009;41:10-14.
89. Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth. 1998;45:10-18.
90. Gundry SR, Drongowski RA, Coran AG, Kirsh MM, Klein MD. Failure of automated protamine titration to determine the protamine reversal dose of systemic heparin: comparison with other methods. Curr Surg. 1986;43:110-112.
91. Wang J, Ma HP, Zheng H. Blood loss after cardiopulmonary bypass, standard vs titrated protamine: a meta-analysis. Neth J Med. 2013;71:123-127.
92. Vonk AB, Veerhoek D, van den Brom CE, van Barneveld LJ, Boer C. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth. 2014;28:235-241.
93. Koster A, Börgermann J, Gummert J, Rudloff M, Zittermann A, Schirmer U. Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost. 2014;20:290-295.
94. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781-785.
95. Carr ME Jr, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res. 1994;75:617-630.
96. Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008;34:73-92.
97. Martin P, Horkay F, Gupta NK, Gebitekin C, Walker DR. Heparin rebound phenomenon-much ado about nothing? Blood Coagul Fibrinolysis. 1992;3:187-191.
98. Taneja R, Marwaha G, Sinha P et al. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery. Can J Anaesth. 2009;56:489-496.
99. Teoh KH, Young E, Blackall MH, Roberts RS, Hirsh J. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg. 2004;128:211-219.
100. Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol. 2008;103:192-196.
101. Boigner H, Lechner E, Brock H, Golej J, Trittenwein G. Life threatening cardiopulmonary failure in an infant following protamine reversal of heparin after cardiopulmonary bypass. Paediatr Anaesth. 2001;11:729-732.
102. Kimmel SE, Sekeres M, Berlin JA, Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg. 2002;94:1402-8, table of contents.
103. Welsby IJ, Newman MF, Phillips-Bute B, Messier RH, Kakkis ED, Stafford-Smith M. Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery. Anesthesiology 2005;102:308-14.
104. Kimmel SE, Sekeres MA, Berlin JA, Goldberg LR, Strom BL. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J Clin Epidemiol. 1998;51:1-10.
105. Ford SA, Kam PC, Baldo BA, Fisher MM. Anaphylactic or anaphylactoid reactions in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2001;15:684-688.
106. Viaro F, Dalio MB, Evora PR. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? Chest. 2002;122:1061-1066.
107. Comunale ME, Maslow A, Robertson LK, Haering JM, Mashikian JS, Lowenstein E. Effect of site of venous protamine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstriction. J Cardiothorac Vasc Anesth. 2003;17:309-313.
108. Ocal A, Kiriş I, Erdinç M, Peker O, Yavuz T, Ibrişim E. Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med. 2005;207:51-58.
109. Olinger GN, Becker RM, Bonchek LI. Noncardiogenic pulmonary edema and peripheral vascular collapse following cardiopulmonary bypass: rare protamine reaction? Ann Thorac Surg. 1980;29:20-25.
110. Pretorius M, Scholl FG, McFarlane JA, Murphey LJ, Brown NJ. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass. Clin Pharmacol Ther. 2005;78:477-485.
111. Lee GM, Welsby IJ, Phillips-Bute B, Ortel TL, Arepally GM. High incidence of antibodies to protamine and protamine/ heparin complexes in patients undergoing cardiopulmonary bypass. Blood. 2013;121:2828-2835.
112. Bakchoul T, Zöllner H, Amiral J et al. Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood. 2013;121:2821-2827.
113. Vincent GM, Janowski M, Menlove R. Protamine allergy reactions during cardiac catheterization and cardiac surgery: risk in patients taking protamine-insulin preparations. Cathet Cardiovasc Diagn. 1991;23:164-168.
114. Bernabei A, Gikakis N, Maione TE et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1995;109:765-771.
115. Levy JH, Cormack JG, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg. 1995;81:35-37.
116. Demma L, Levy JH. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. Anesth Analg. 2012;115:1273-1278.
117. Kikura M, Lee MK, Levy JH. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. Anesth Analg. 1996;83:223-227.
118. Stafford-Smith M, Lefrak EA, Qazi AG, et al. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005;103:229-40.